157 related articles for article (PubMed ID: 32285033)
1. The Correlation of Magee Equations
Soran A; Tane K; Sezgin E; Bhargava R
Eur J Breast Health; 2020 Apr; 16(2):117-123. PubMed ID: 32285033
[TBL] [Abstract][Full Text] [Related]
2. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
3. The Role of Oncotype DX
Pardo JA; Fan B; Mele A; Serres S; Valero MG; Emhoff I; Alapati A; James TA
Ann Surg Oncol; 2021 Mar; 28(3):1320-1325. PubMed ID: 33393046
[TBL] [Abstract][Full Text] [Related]
4. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
5. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Farrugia DJ; Landmann A; Zhu L; Diego EJ; Johnson RR; Bonaventura M; Soran A; Dabbs DJ; Clark BZ; Puhalla SL; Jankowitz RC; Brufsky AM; Lembersky BC; Ahrendt GM; McAuliffe PF; Bhargava R
Mod Pathol; 2017 Aug; 30(8):1078-1085. PubMed ID: 28548119
[TBL] [Abstract][Full Text] [Related]
6. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
[TBL] [Abstract][Full Text] [Related]
7. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
8. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
[TBL] [Abstract][Full Text] [Related]
10. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
Sughayer M; Alaaraj R; Alsughayer A
Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
[TBL] [Abstract][Full Text] [Related]
11. Oncotype DX
Pease AM; Riba LA; Gruner RA; Tung NM; James TA
Ann Surg Oncol; 2019 Feb; 26(2):366-371. PubMed ID: 30542840
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
13. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
[TBL] [Abstract][Full Text] [Related]
14. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
Thibodeau S; Voutsadakis IA
Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
[TBL] [Abstract][Full Text] [Related]
15. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
16. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
[TBL] [Abstract][Full Text] [Related]
17. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
18. Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score
Boolbol SK; Harshan M; Chadha M; Kirstein L; Cohen JM; Klein P; Anderson J; Davison D; Jakubowski DM; Baehner FL; Malamud S
Breast Cancer Res Treat; 2019 Oct; 177(3):611-618. PubMed ID: 31302854
[TBL] [Abstract][Full Text] [Related]
19. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study.
Nam G; Singh K; Lopresti ML; Ouseph MM; Wang LJ; Wang Y
Technol Cancer Res Treat; 2021; 20():15330338211035037. PubMed ID: 34696631
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]